February 10, 2025
This article describes how Tecentriq Hybreza (atezolizumab and hyaluronidase) became the first injectable anti-PD-L1 immunotherapy approved by the FDA, followed by the December approval of Opdivo Qvantig (nivolumab and hyaluronidase) to treat a range of cancers including melanoma, lung, liver, and skin cancers. Clinical trials showed similar effectiveness between injection and infusion methods, with patients expressing a strong preference for the shorter, more comfortable injection process.
Dr. Khasraw was featured in this article to emphasize the potential advantages of injectable immunotherapy beyond convenience. He pointed to possible cost reductions due to shorter clinic visits and even the future prospect of self-administration. However, he cautioned that more long-term data are needed to ensure that injectable forms are as effective over time as traditional IV methods. He also highlighted scenarios where IV delivery might still be preferred, such as in patients receiving multiple therapies or with skin conditions affecting drug absorption.
Read the full article here.